1. Home
  2. PLRX vs ATRO Comparison

PLRX vs ATRO Comparison

Compare PLRX & ATRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • PLRX
  • ATRO
  • Stock Information
  • Founded
  • PLRX 2015
  • ATRO 1968
  • Country
  • PLRX United States
  • ATRO United States
  • Employees
  • PLRX N/A
  • ATRO N/A
  • Industry
  • PLRX Biotechnology: Pharmaceutical Preparations
  • ATRO Military/Government/Technical
  • Sector
  • PLRX Health Care
  • ATRO Industrials
  • Exchange
  • PLRX Nasdaq
  • ATRO Nasdaq
  • Market Cap
  • PLRX 680.3M
  • ATRO 592.4M
  • IPO Year
  • PLRX 2020
  • ATRO N/A
  • Fundamental
  • Price
  • PLRX $11.37
  • ATRO $18.38
  • Analyst Decision
  • PLRX Strong Buy
  • ATRO Hold
  • Analyst Count
  • PLRX 7
  • ATRO 1
  • Target Price
  • PLRX $40.50
  • ATRO $17.00
  • AVG Volume (30 Days)
  • PLRX 485.5K
  • ATRO 259.9K
  • Earning Date
  • PLRX 02-26-2025
  • ATRO 02-26-2025
  • Dividend Yield
  • PLRX N/A
  • ATRO N/A
  • EPS Growth
  • PLRX N/A
  • ATRO N/A
  • EPS
  • PLRX N/A
  • ATRO N/A
  • Revenue
  • PLRX N/A
  • ATRO $782,178,000.00
  • Revenue This Year
  • PLRX N/A
  • ATRO $15.96
  • Revenue Next Year
  • PLRX N/A
  • ATRO $7.32
  • P/E Ratio
  • PLRX N/A
  • ATRO N/A
  • Revenue Growth
  • PLRX N/A
  • ATRO 19.95
  • 52 Week Low
  • PLRX $10.22
  • ATRO $14.13
  • 52 Week High
  • PLRX $18.00
  • ATRO $23.74
  • Technical
  • Relative Strength Index (RSI)
  • PLRX 44.60
  • ATRO 72.13
  • Support Level
  • PLRX $10.35
  • ATRO $16.77
  • Resistance Level
  • PLRX $11.07
  • ATRO $17.95
  • Average True Range (ATR)
  • PLRX 0.61
  • ATRO 0.58
  • MACD
  • PLRX 0.06
  • ATRO 0.16
  • Stochastic Oscillator
  • PLRX 43.50
  • ATRO 90.43

About PLRX Pliant Therapeutics Inc.

Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.

About ATRO Astronics Corporation

Astronics Corp supplies products to the aerospace, defense, and electronics industries. The company has two reportable segments namely Aerospace and Test Systems. The aerospace segment serves three primary markets: military, commercial transport, and General Aviation. The Test Systems segment serves the aerospace, defense, and semiconductor markets. The company generates a majority of its revenue from the Aerospace segment. Geographically, it generates a majority of its revenue from the United States.

Share on Social Networks: